CompletedPhase 2NCT00117975
Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
Studying Follicular lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alliance for Clinical Trials in Oncology
- Principal Investigator
- Myron S. Czuczman, MDRoswell Park Cancer Institute
- Intervention
- galiximab(biological)
- Enrollment
- 62 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2005 – 2013
Study locations (30)
- Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington D.C., District of Columbia, United States
- Michael & Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital, Fort Lauderdale, Florida, United States
- Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, United States
- Ella Milbank Foshay Cancer Center at Jupiter Medical Center, Jupiter, Florida, United States
- CCOP - Mount Sinai Medical Center, Miami Beach, Florida, United States
- Graham Hospital, Canton, Illinois, United States
- Memorial Hospital, Carthage, Illinois, United States
- University of Chicago Cancer Research Center, Chicago, Illinois, United States
- Eureka Community Hospital, Eureka, Illinois, United States
- Galesburg Clinic, Galesburg, Illinois, United States
- Galesburg Cottage Hospital, Galesburg, Illinois, United States
- Mason District Hospital, Havana, Illinois, United States
- Hopedale Medical Complex, Hopedale, Illinois, United States
- Kewanee Hospital, Kewanee, Illinois, United States
- McDonough District Hospital, Macomb, Illinois, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00117975 on ClinicalTrials.govOther trials for Follicular lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07128641Odronextamab in Low Tumor Volume Advanced FLGottfried von Keudell, MD PhD
- RECRUITINGNANCT07126678Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular LymphomaThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGEARLY PHASE1NCT06976437A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant TumorsYANRU WANG
- RECRUITINGNCT06794268A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing SettingJuno Therapeutics, Inc., a Bristol-Myers Squibb Company
- RECRUITINGPHASE1NCT07093073Clinical Study of U01（ssCART-19） in Patients With B-Cell LymphomaShanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
- RECRUITINGPHASE2NCT06959732Zanubrutinib Combined With G-CVP in Previously Untreated FLCancer Institute and Hospital, Chinese Academy of Medical Sciences
- RECRUITINGEARLY PHASE1NCT06662227Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell TumorsWondercel Biotech (ShenZhen)
- RECRUITINGPHASE3NCT06549595A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma PatientsAstraZeneca